Cara Therapeutics regained compliance with Nasdaq's minimum bid price requirement after its stock price was above $1.00 for ten consecutive days, and received an extension until May 19, 2025, to meet the stockholders equity requirement of $2.5 million, as it currently stands at $707,000.